News Release
2017.04.04
New Study Reveals Economic Impact of Patients with Traumatic Brain Injury（140KB）
Info
2017.03.27
SanBio’s Assoc. Director of Research, Yaisa Andrews-Zwilling, PhD, will present at the Morgan Stanley Women’s Intelligence Trust and talk about the data from our clinical trial on April 5th, 2017.Please see the following link for more information on the Women’s Intelligence Trust: http://www.womensintelligencetrust.com/home/
News Release
2017.02.27
Study of SanBio’s Stem Cell Treatment for Stroke Receives Innovation Award from American Heart Association（168KB）
Info
2017.01.10
SanBio to Present at the 35th Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2017 at 11:00am PT
Info
2016.11.09
Dr. Damien Bates, Chief Medical Officer and Head of Research at SanBio will speak on a panel at 2016 World Alliance Forum in San Francisco on November 21
Info
2016.11.07
SanBio Presents Interim Results of the First Intracerebral Stem Cell Transplant Study for Stroke in the United States
News Release
2016.10.26
First Patient is Enrolled in Global STEMTRA Trial for Traumatic Brain Injury in Japan（187KB）
Info
2016.10.17
Dr. Damien Bates, Chief Medical Officer and Head of Research at SanBio will speak on a panel at AusBiotech 2016 on October 25 in Melbourne, Australia
Info
2016.09.16
Dr. Damien Bates, Chief Medical Officer and Head of Research at SanBio will speak at th 75th Annual Meeting of the Japan Neurosurgical Society on September 29 in Fukuoka, Japan
News Release
2016.07.11
First Patient is Randomized in STEMTRA Trial For Traumatic Brain Injury（92KB）
News Release
2025.02.12
Publication of Results of Cell Implantation Location Analysis from Phase 2 Clinical Trial of Vandefitemcel (SB623) in TBI Patients (STEMTRA Trial) in Neurotrauma Reports
News Release
2025.02.06
The Results of the Second Commercial Production Run to Meet the Approval Conditions for the Shipment of AKUUGO🄬 Suspension for Intracranial Implantation
News Release
2025.01.07
Publication of an Article in Molecular Therapy Demonstrates That SB623 ImprovesCortical Excitability in Rats with Focal Cerebral Ischemia
News Release
2024.12.06
The Yield Results of the Second Commercial Production Run for AKUUGO🄬 Suspension for Intracranial Implantation
News Release
2024.11.15
The Results of the First Commercial Production Run to Meet the Approval Conditions for the Shipment of AKUUGO🄬 Suspension for Intracranial Implantation
News Release
2024.09.05
Positive Results of Key Development Product SB623 for Chronic Effects of Traumatic Brain Injury, including Sustained Motor Function Improvement up to 48 weeks, published in Neurology
News Release
2024.07.31
SanBio Obtains Marketing Approval for “AKUUGO🄬 Suspension for Intracranial Implantation” (INN: Vandefitemcel) as a Therapeutic Agent for Improving Chronic Motor Paralysis From Traumatic Brain Injury (TBI)
News Release
2024.07.29
Notice Concerning Notice of Allowance of New Patent for Cell Therapy Using SB623 for Chronic Ischemic Stroke in the US
News Release
2024.07.10
[Results of Basic Research] Publication of an Article on the Neuronal Activity and Network Formation Promotion of the Key Development Product SB623
News Release
2024.06.20
Further Update on Status of Manufacturing and Marketing Approval for SB623 Chronic Traumatic Brain Injury (TBI) Program in Japan
Media
2022.04.08
On April 7, NeurologyLive published an interview with Dr. Peter McAllister regarding the final analysis of the Phase 2 STEMTRA trial.
Media
2018.04.20
Dr. Damien Bates, Chief Medical Officer and Head of Research at SanBio, publishes report in the leading medical journal, Stroke
Info
2025.01.14
Sawaguchi, Head of Japan Regulatory Affairs & Quality Compliance Japan, will speak at 【Regenerative Medicine Seminar 2024】“Development of Regenerative Medicine Products: Recent Trends in Regenerative Medicine and Other Related Issues” (Vol.5: Quality in Regenerative Medicine Products)” hosted by the Clinical and Translational Research Center (CTR) Keio University Hospital
Info
2024.11.11
MORI, President & CEO, will be a panelist at “Navigating Biopharma Innovation Across the Pacific” hosted by the U.S. Embassy and the Japan Society of Northern California on November 11
Info
2022.12.22
Presentation of Phase 2 STEMTRA Trial Results at The 14th World Congress on Brain Injury
Info
2021.02.22
Head of Regulatory Affairs Japan, Kazumi Sawaguchi, Ph.D., gave a presentation at 5th DIA Cell and Gene Therapy Products Symposium in Japan
Info
2021.01.06
SanBio to Present at the 39th Annual J.P. Morgan Healthcare Conference
Info
2019.12.16
Message from Representative Director and President, Keita Mori, regarding disclosures made on December 13, 2019
Info
2018.12.27
【Announcement】SanBio will present at the 37th Annual J.P. Morgan Healthcare Conference
Info
2018.08.28
【Announcement】SanBio will be featured on NHK WORLD – JAPAN “Medical Frontiers – The Brain Can Be Regenerated” on September 4 (Tue) 4 times a day, Japan timeIt is available for watching on the Internet.
Info
2018.01.10
SanBio presented at the 36th Annual J.P. Morgan Healthcare Conference
Info
2017.11.22
Keita Mori, CEO of SanBio will speak at 2017 World Alliance Forum in San Francisco on November30
